Citations

Showing 10 of 108104 citations.

Front Cover: Synthesis, Computational Docking Study, and Biological Evaluation of a Library of Heterocyclic Curcuminoids with Remarkable Antitumor Activity (ChemMedChem 18/2018)
Greves, William J., Zwarycz, Angela T. , Smits, Sebastian J. Correa, Troendle, Frederick J., Borosky, Gabriela L. , Chanan‐Khan, Asher , Laali, Kenneth K. , Akhtar, Sharoon , Manna, Alak , Paulus, Aneel , Nukaya, Manabu , Kennedy, Gregory D.

Mayo Clinic

ChemMedChem | September 19, 2018 | Volume: 13 | Issue: 18 | Pages: 1853-1853

10.1002/cmdc.201800584 Get It

A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human Glioma
Koehler, Jennifer W. , Miller, Andrew D. , Miller, C. Ryan , Aldape, Kenneth , Beck, Jessica A. , Corps, Kara N. , Frank, Chad , O’Sullivan, M. Gerard , Rissi, Daniel R. , Simpson, R. Mark , Woolard, Kevin , Shih, Joanna H. , Mazcko, Christina , O’Sullivan, M. Gerard , O'Sullivan, M Gerard , Porter, Brian F. , Brat, Daniel J. , Cornax, Ingrid , Giannini, Caterina , Horbinski, Craig , Huse, Jason T. , Gilbert, Mark R. , LeBlanc, Amy Kathleen

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | September 19, 2018 | Volume: 77 | Issue: 11 | Pages: 1039-1054

10.1093/jnen/nly085 | PMID 30239918 Get It

Microbiota-sensitive epigenetic signature predicts inflammation in Crohn’s disease
Kotliar, Michael , Woo, Vivienne , Jagannathan, Sajjeev , Whitt, Jordan , Moncivaiz, Jessica, Aronow, Bruce J. , Dubinsky, Marla C. , Hyams, Jeffrey S. , Markowitz, James , Baldassano, Robert N. , Stephens, Michael C., Walters, Thomas D. , Haberman, Yael , Sundaram, Nambirajan , Rosen, Michael J. , Helmrath, Michael A. , Barski, Artem , Denson, Lee A. , Alenghat, Theresa , Kelly, Daniel, Kugathasan, Subra , Karns, Rebekah A.

Mayo Clinic

JCI Insight | September 19, 2018 | Volume: 3 | Issue: 18 | Pages: No page available

10.1172/jci.insight.122104 | PMID 30232290 Get It

Altered response to the intestinal microbiota strongly associates with inflammatory bowel disease (IBD); however, how commensal microbial cues are integrated by the host during the pathogenesis of IBD is not understood. Epigenetics represents a potential mechanism that could enable intestinal microbes to modulate transcriptional output during the development of IBD. Here, we reveal a histone methylation signature of intestinal epithelial cells isolated from the terminal ilea of newly diagnosed pediatric IBD patients. Genes characterized by significant alterations in histone H3-lysine 4 trimethylation (H3K4me3) showed differential enrichment in pathways involving immunoregulation, cell survival and signaling, and metabolism. Interestingly, a large subset of these genes was epigenetically regulated by microbiota in mice and several microbiota-sensitive epigenetic targets demonstrated altered expression in IBD patients. Remarkably though, a substantial proportion of these genes exhibited H3K4me3 levels that correlated with the severity of intestinal inflammation in IBD, despite lacking significant differential expression. Collectively, these data uncover a previously unrecognized epigenetic profile of IBD that can be primed by commensal microbes and indicate sensitive targets in the epithelium that may underlie how microbiota predispose to subsequent intestinal inflammation and disease.
Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events: Methods for item selection in industry-sponsored oncology clinical trials
Trask, Peter C., Dueck, Amylou C. , Piault, Elisabeth , Campbell, Alicyn, Dueck, A. C.

Mayo Clinic

Clinical Trials | September 19, 2018 | Volume: 15 | Issue: 6 | Pages: 616-623

10.1177/1740774518799985 | PMID 30230365 Get It

As new cancer treatment regimens demonstrate increased potential to improve patients’ survival, more focus is directed toward the quality of that extension of life and to obtaining additional information from patients regarding their experience with treatment. The utility of capturing patient-reported treatment-related symptoms to complement traditional clinician-rated symptomatic adverse event reporting is well-documented. The National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events is an item library aimed at capturing patient-reported symptoms to inform the patient perspective on a treatment’s tolerability. The U.S. Food and Drug Administration has recommended using the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events in clinical trials. A practical guideline is needed to inform a priori selection of specific Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events items for use in any given industry-sponsored oncology clinical trial. Standardizing this selection process will foster systematic and consistent data collection as part of drug development and enhance our knowledge on how to use patient-relevant information as part of a treatment’s risk/benefit assessment. This article presents methods and consensus recommendations for selecting specific Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events items to include in early-phase and late-phase oncology clinical trials.
P05.93 Adult medulloblastoma: analysis of use of chemotherapy in clinical practice
Mastall, Max , Majd, Nazanin , Gule-Monroe, Maria , Khatua, Soumen , Rao, Ganesh , Sandberg, David I. , Zaky, Wafik , Mahajan, Anita , Suki, Dima , Alfaro, Kristin D, Weathers, Shiao‐Pei , Peñas-Prado, Marta , Fuller, Gregory N. , Huse, Jason T. , Wefel, Jeffrey S. , Yeboa, D.N. , Puduvalli, Vinay K. , Harrison, Rebecca A , Groot, John de

Mayo Clinic

Neuro-Oncology | September 19, 2018 | Volume: 20 | Issue: suppl_3 | Pages: iii325-iii325

10.1093/neuonc/noy139.419 Get It

Performance/outcomes data and physician process challenges for practical big data efforts in radiation oncology
Matuszak, M.M. , Fuller, Clifton D. , Yock, Torunn I. , McNutt, Todd , Jolly, Shruti , Mayo, Charles S. , Thor, Maria, Caissie, Amanda, Rao, Arvind , Owen, Dawn , Smith, W. P., Palta, Jatinder , Kapoor, Rishabh , Hayman, James A. , Waddle, Mark R. , Rosenstein, Barry S. , Miller, Robert C. , Moreno, Amy C. , Herman, Joseph M. , Feng, Mary, Waddle, Mark, Hess, Clayton Burnett , Gabriel, Peter , Choi, Seungtaek L. , Fuller, Clifton David

Mayo Clinic

Medical Physics | September 19, 2018 | Volume: 45 | Issue: 10 | Pages: No page available

10.1002/mp.13136 | PMID 30229946 Get It

It is an exciting time for big data efforts in radiation oncology. The use of big data to help aid both outcomes and decision‐making research is becoming a reality. However, there are true challenges that exist in the space of gathering and utilizing performance and outcomes data. Here, we summarize the current state of big data in radiation oncology with respect to outcomes and discuss some of the efforts and challenges in radiation oncology big data.
A feasibility study on identifying drinking-related contents in Facebook through mining heterogeneous data
ElTayeby, Omar , Eaglin, Todd, Abdullah, Malak , Burlinson, David, Dou, Wenwen , Yao, Lixia

Mayo Clinic

Health Informatics Journal | September 19, 2018 | Volume: 25 | Issue: 4 | Pages: 1756-1767

10.1177/1460458218798084 | PMID 30230403 Get It

Binge drinking is a severe health problem faced by many US colleges and universities. College students often post drinking-related text and images on social media, portraying their alcohol use as socially desirable. In this project, we investigated the feasibility of mining the heterogeneous data (e.g. text, images, and videos) on Facebook to identify drinking-related contents. We manually annotated 4266 posts during 21 October 2011 and 3 November 2014 from “I’m Shmacked” group on Facebook, where 511 posts were drinking-related. Our machine learning models show that by combining heterogeneous data types, we were able to identify drinking-related posts with an F1-score of 0.81. Prediction models built on text data were more reliable compared to those built on image and video data for predicting drinking-related contents. As the first step of our efforts in this direction, this feasibility study showed promise toward unleashing the potential of mining social media to identify students who binge drink.
Comparable functional motor outcomes after repair of peripheral nerve injury with an elastase‐processed allograft in a rat sciatic nerve model
Hundepool, Caroline A. , Bulstra, Liselotte F. , Kotsougiani, Dimitra , Friedrich, Patricia F. , Hovius, Steven E.R., Bishop, Allen T. , Shin, Alexander Y.

Mayo Clinic

Microsurgery | September 19, 2018 | Volume: 38 | Issue: 7 | Pages: 772-779

10.1002/micr.30371 | PMID 30230005 Get It

AbstractBackgroundA bridging nerve autograft is the gold standard for the repair of segmental nerve injury that cannot be repaired directly. However, limited availability and donor site morbidity remain major disadvantages of autografts. Here, a nerve allograft decellularized with elastase was compared with an autograft regarding functional motor outcome in a rat sciatic segmental nerve defect model. Furthermore, the effect of storage on this allograft was studied.MethodsSixty‐six Lewis rats (250–300 g) underwent a 10‐mm sciatic nerve reconstruction using either a cold‐ (n = 22) or frozen‐stored (n = 22) decellularized nerve allograft or an autograft (n = 22). Sprague–Dawley rats (300–350 g) served as full major histocompatibility complex‐mismatched donors. Functional motor outcome was evaluated after 12 and 16 weeks. Ankle angle, compound muscle action potential (CMAP), isometric tetanic force, wet muscle weight, and histomorphometry were tested bilaterally.ResultsFor CMAP and isometric tetanic force, no significant differences were observed between groups. In contrast, for ankle angle, histomorphometry and muscle weight, the cold‐stored allograft performed comparable to the autograft, while the frozen‐stored allograft performed significantly inferior to the autograft. At week 16, ankle angle was 88.0 ± 3.1% in the cold‐stored group, 77.4 ± 3.6% in the frozen‐stored group, and 74.1 ± 3.1% in the autograft group (P < .001); At week 16, the muscle weight showed a recovery up to 71.1 ± 4.8% in the autograft group, 67.0 ± 6.6% in the cold‐stored group, and 64.7 ± 3.7% in the frozen‐stored group (P < .05).ConclusionsA nerve allograft decellularized with elastase, if stored under the right conditions, results in comparable functional motor outcomes as the gold standard, the autograft.
Cutaneous effects associated with fluconazole in patients treated for coccidioidomycosis
Brewer, Ann Chang, Huber, Jordan, Girardo, Marlene , Burns, Mark W. , Stewart, Terry D., Blair, Janis E. , Huber, Jordan T, Kosiorek, Heidi , Burns, Mark W.

Mayo Clinic

International Journal of Dermatology | September 19, 2018 | Volume: 58 | Issue: 2 | Pages: 250-253

10.1111/ijd.14238 | PMID 30229876 Get It

AbstractBackgroundFluconazole is the most commonly used antifungal treatment for various forms of coccidioidomycosis. Although we had anecdotally observed a high proportion of patients reporting cutaneous adverse effects associated with fluconazole treatment, this observation was not well described in the medical literature, and we were unsure of the additional effect of the arid desert environment of Arizona.MethodsWe performed a one‐time, voluntary survey of patients with coccidioidomycosis and compared the responses of patients treated with fluconazole with those of untreated patients.ResultsFrom January 1, 2015, to August 22, 2017, 62 fluconazole‐treated and 35 untreated patients with coccidioidomycosis provided consent and were enrolled in the study; demographics were similar between the two groups. Among the 62 fluconazole‐treated patients, daily dosages ranged from 200 mg to 800 mg. However, most (44/62, 71%) took 400 mg daily, the typical dose for the treatment of coccidioidomycosis. The median fluconazole treatment duration at the time of study participation was 6 months. When compared with untreated patients, those taking fluconazole had more moderate to severe dry lips (74.2% [46/62] vs. 23.5% [8/34]; P < 0.001), dry skin (45.8% [27/59] vs. 22.9% [8/35]; P = 0.03), and alopecia (31.1% [19/61] vs. 11.4% [4/35]; P = 0.004).ConclusionsFor the treatment of coccidioidomycosis, patients receiving fluconazole reported significantly more severe cutaneous effects, including dry lips, dry skin, and alopecia, than untreated patients. Our findings identify an association but do not prove causality.